-
Mashup Score: 4Highlights from the EBMT-EHA CAR T-cell 2022 Meeting - 2 year(s) ago
VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell Meeting, which was held virtually from 10–12 February 2022.
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, discusses the potential of engineered immune cell therapies such as chimeric antigen…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exploring the applications of CAR-Ts beyond hematology and oncology w/ Michael Hudecek (@Uni_WUE): 👉https://t.co/ieyeB6YeDN👈 @TheEBMT @EHA_Hematology #CART22 #CART #CARTcell #CARTtherapy #ImmunoOnc #HemOnc #tcellrx #IDTwitter
-
-
Mashup Score: 1Highlights from the EBMT-EHA CAR T-cell 2022 Meeting - 2 year(s) ago
VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell Meeting, which was held virtually from 10–12 February 2022.
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find the most important updates in #CART from #CART22 in our new feature 💉 👉https://t.co/8IZYUhNlC9👈 Ft. exclusive insights from Michael Hudecek , @Mohty_EBMT, Ulrich Jäger & Michael Schmitt 🔎 @TheEBMT @EHA_Hematology #CARTtherapy #CARTcell #tcellrx #ImmunoOnc #HemOnc
-
-
Mashup Score: 4Tabelecleucel as an alternative treatment option in patients following transplantation - 2 year(s) ago
AJ Joshi, MD, Atara Biotherapeutics, San Francisco, CA, discusses alternative treatment options for patients who undergo solid organ transplant (SOT)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
AJ Joshi of @Atarabio shares some insights into the use of tabelecleucel as an alternative treatment option in patients following transplantation: 👉https://t.co/8KzzxTWOM9👈 @ASH_hematology #ASH21 #HemOnc #ImmunoOnc #CART #CARTTherapy #tcellrx #Lymphoma #LymSM
-
-
Mashup Score: 5Minimizing the costs of CAR-T manufacturing - 2 year(s) ago
Ulrike Koehl, MD, PhD, University of Leipzig, Leipzig, Germany, outlines strategies to reduce the costs associated with chimeric antigen receptor…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Minimizing the costs of CAR-T manufacturing | Ulrike Koehl of @UniLeipzig shares her thoughts. Watch now: 👉https://t.co/nrOedx2GUm👈 @TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #CART #tcellrx
-
-
Mashup Score: 0
The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We're so excited about the recent approval of cilta-cel for the treatment of relapsed/refractory multiple myeloma!💉 Read more about it here: 👉https://t.co/BuGsjl4Dqt👈 #MMsm #Myeloma #CART #tcellrx #CARTTherapy #MultipleMyeloma #HemOnc #ImmunoOnc
-
-
Mashup Score: 2Highlights from the EBMT-EHA CAR T-cell 2022 Meeting - 2 year(s) ago
VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell Meeting, which was held virtually from 10–12 February 2022.
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 Missed #CART22? Don’t worry! Find the most important updates in #CARTtherapy in #HemOnc in our new feature 💉🩸 👉https://t.co/CWCeae8j4N👈 @TheEBMT @EHA_Hematology #ImmunoOnc #CART #CARTcell #tcellrx #MMsm #LYMsm #ALLsm #CTSM #TrialUpdate
-
-
Mashup Score: 1Managing patients with hematological malignancies treated with CAR-Ts during the COVID-19 pandemic - 2 year(s) ago
Raffaella Greco, MD, PhD, San Raffaele Hospital, Milan, Italy, talks on managing patients with hematological malignancies treated with chimeric antigen…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Raffaella Greco of @SanRaffaeleMI talks on managing patients treated with CAR-Ts during the COVID-19 pandemic. Watch: 👉https://t.co/e2MlfbhVRp👈 @TheEBMT @EHA_Hematology #CART22 #CARTtherapy #ImmunoOnc #HemOnc #CART #tcellrx
-
-
Mashup Score: 1
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the results of the ZUMA-7…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-T therapy in second-line for NHL: ZUMA-7, TRANSFORM & BELINDA - @AnnaSureda5 shares her thoughts. Watch her interview now: 👉https://t.co/56lLXk5Sxb👈 @TheEBMT @EHA_Hematology #CART22 #Lymphoma #LymSM #TrialUpdates #CARTtherapy #ImmunoOnc #HemOnc #CART #tcellrx
-
-
Mashup Score: 0
The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 The recent FDA approval of cilta-cel for the treatment of R/R multiple myeloma is a huge step forward for the myeloma community! Read more about it in our feature article: 👉https://t.co/gZg6cXUCna 👈 #MMsm #Myeloma #CART #CARTTherapy #tcellrx #MyelomaAwarenessMonth
-
📣 The most exciting updates shared at #CART22 📣 ⬇️⬇️⬇️ https://t.co/7dccvukIvu @TheEBMT @EHA_Hematology #CARTtherapy #CART #tcellrx #ImmunoOnc #HemOnc #MMsm #LYMsm #ALLsm #CARTcell #CTSM #TrialUpdate